Prurigo Nodularis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

October 15 00:15 2022
Prurigo Nodularis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Prurgio Nodularis Market:
DelveInsight’s Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Prurigo Nodularis market report provides current treatment practices, emerging drugs, Prurigo Nodularis market share of the individual therapies, current and forecasted Prurigo Nodularis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Prurigo Nodularis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Prurigo Nodularis market.

Some of the key facts of the Prurigo Nodularis  Market Report:

  • As per DelveInsight’s analysis, it has been observed that most of the patients with PN are diagnosed with atopic PN in comparison with non-atopic PN.
  • Among the European 5 countries, Germany had the highest prevalent population of PN, followed by France and Italy. On the other hand, Spain had the lowest prevalent population of PN.
  • Japan had 83,832 patients affected with PN in 2021, which is expected to increase in the forecast period (2019-2032).  

.

Key benefits of the report:

  • The report covers the descriptive overview of Prurigo Nodularis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Prurigo Nodularis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Prurigo Nodularis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Prurigo Nodularis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Prurigo Nodularis market

Got queries? Click here to know more about the Prurigo Nodularis Market Insights 

Prurigo Nodularis  Overview

Prurigo nodularis (PN) is an intensely pruritic, chronic inflammatory skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution. PN is accompanied by long-standing pruritus and is thought to develop as a reaction to repeated scratching in patients with Chronic Prurigo (CP) from various etiologies, including dermatological, systemic, infectious, and psychiatric. The disease is characterized by hyperkeratotic, crusted or excoriated, light-red to bright-red papules, nodules, or plaques with hyperpigmented margins as distinguishing features. 

Existing treatments aim to interrupt the vicious itch-scratch cycle. The current treatment includes topical steroids, systemic steroids, intralesional steroids, immunosuppressants and immunomodulators, and other classes including antihistamines, antidepressants, anticonvulsants, and opioid receptor modulators. The market is expected to grow due to the expected entry of emerging therapies with novel targets and pricing. Furthermore, the upcoming products such as Nemolizumab, Dupixent, Vixarelimab, Nalbuphine ER, and Serlopitant are anticipated to expand the market, with deeper penetration, in the 7MM. 

Prurigo Nodularis Epidemiological Insights

 

  • The total diagnosed prevalent population of Postpartum Depression in the 7MM was found to be  553,469

in 2021. 

  • The United States had the largest share in the total diagnosed prevalent patient population in the 7MM, having a total of 258,998 cases in 2021. 

 

Prurigo Nodularis   Epidemiological Segmentation 

  • Total  Prurgio Nodularis diagnosed Prevelant cases
  • Total  Prurgio Nodularis gender-specific Diagnosed Prevalent cases
  • Total Prurgio Nodularis type-specific Diagnosed Prevalent cases 
  • Total Prurgio Nodularis severity specific diagnosed prevalent cases
  • Total Prurgio Nodularis age-specific diagnosed specific cases

Prurgio Nodularis  Market Outlook

The Prurigo Nodularis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Prurigo Nodularis market trends by analyzing the impact of current Prurigo Nodularis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of Prurigo Nodularis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Prurigo Nodularis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Prurigo Nodularis market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @ Prurigo Nodularis Market Landscape

Prurgio Nodularis Key Companies

  • Sanofi
  • Amgen
  • Kiniksa Pharmaceuticals
  • And many more

 

Prurgio Nodularis Therapies 

  • Dupixent
  • Apremilast
  • KPL-716
  • And many more

 

Market Drivers 

  • Government Initiatives
  • Pipeline Advancements and various off-label therapies
  • Growth in Research and Development
  • Increase in the number of patients

 

Market Barriers 

 

  • Disease-related challenges in terms of pathophysiology and management
  • Lack of Clinical Trial Data

 

Table of Contents

  • Key Insights 
  •  Report Introduction 
  •  Executive Summary of Prurgio Nodularis 
  •  Disease Background and Overview
  •  Epidemiology and patient population 
  •  Prurgio Nodularis   Emerging Therapies
  •  Prurgio Nodularis  Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  •  Prurgio Nodularis  Report Methodology
  •  DelveInsight Capabilities
  •  Disclaimer
  • About DelveInsight

Click here to read more about Prurigo NodularisMarket Insights  

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/